We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

72 hedge funds and large institutions have $121M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more call options, than puts

Call options by funds: $72K | Put options by funds: $6K

1% more funds holding

Funds holding: 71 → 72 (+1)

4% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 28

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

48% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 23

55% less capital invested

Capital invested by funds: $270M → $121M (-$149M)

Holders
72
Holders Change
+1
Holders Change %
+1.41%
% of All Funds
1.13%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
29
Increased
12
Reduced
23
Closed
28
Calls
$72K
Puts
$6K
Net Calls
+$66K
Net Calls Change
-$137K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$11M
2
FCMV
Foresite Capital Management V
California
+$5.98M
3
Millennium Management
Millennium Management
New York
+$3.48M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.55M
5
Renaissance Technologies
Renaissance Technologies
New York
+$876K

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$26.7M
2
APM
Avidity Partners Management
Texas
-$7.25M
3
WP
Woodline Partners
California
-$6.81M
4
BlackRock
BlackRock
New York
-$5.99M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$348K -$69.5K -18,034 -14%
Two Sigma Investments
27
Two Sigma Investments
New York
$344K +$438K +113,503 New
CSS
28
Cubist Systematic Strategies
Connecticut
$336K +$428K +110,912 New
Marshall Wace
29
Marshall Wace
United Kingdom
$329K +$418K +108,450 New
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$315K +$400K +103,881 New
Verition Fund Management
31
Verition Fund Management
Connecticut
$283K +$360K +93,345 New
Charles Schwab
32
Charles Schwab
California
$280K -$188K -48,737 -35%
Morgan Stanley
33
Morgan Stanley
New York
$277K +$195K +50,677 +125%
DCM
34
DAFNA Capital Management
California
$243K -$3.2K -829 -1%
XT
35
XTX Topco
Cayman Islands
$219K +$279K +72,300 New
CIC
36
Cornercap Investment Counsel
Georgia
$206K +$262K +68,040 New
State Street
37
State Street
Massachusetts
$188K -$1.56M -404,422 -87%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$182K +$232K +60,109 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$163K +$208K +53,826 New
JF
40
Jump Financial
Illinois
$141K +$179K +46,433 New
YIH
41
Y-Intercept (HK)
Hong Kong
$102K +$130K +33,702 New
Man Group
42
Man Group
United Kingdom
$101K +$129K +33,473 New
PCM
43
Prelude Capital Management
New York
$87.1K +$111K +28,754 New
Northern Trust
44
Northern Trust
Illinois
$84.9K -$709K -183,846 -87%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$77.8K -$26.8K -6,962 -21%
PFCS
46
Pale Fire Capital SE
Czech Republic
$71.8K +$91.3K +23,682 New
VF
47
Virtu Financial
New York
$62K +$79.4K +20,585 New
LCM
48
Laurion Capital Management
New York
$60.8K +$77.4K +20,075 New
OMC
49
Old Mission Capital
Illinois
$59.7K +$76K +19,704 New
Two Sigma Advisers
50
Two Sigma Advisers
New York
$52.7K +$67.1K +17,400 New
1
2
3 4

KNTE Hedge Fund Activity: Q2 2023 in Review

72 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q2 2023, worth a combined $121M — down 55% from $270M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new KNTE positions and 28 closed out — a net gain of 1 holder — while 12 added to existing stakes and 23 trimmed.

The largest buyer was OrbiMed, adding an estimated $11M. The largest seller was RA Capital Management, exiting entirely with an estimated $26.7M sold.

  • 72 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q2 2023, up from 71 in Q1 2023.
  • Funds reported $121M of Kinnate Biopharma Inc. Common Stock stock for Q2 2023, down 55% quarter-over-quarter.
  • 29 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q2 2023 and 28 closed out, a net change of +1 holder.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q2 2023 was OrbiMed, an estimated $11M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q2 2023 was RA Capital Management, an estimated $26.7M sold.

Based on aggregated 13F filings for Q2 2023.